表紙
市場調查報告書

Medsuite:澳洲的整形外科生醫材料市場 (2020-2026年)

Orthopedic Biomaterials Market Report Suite | Australia | 2020-2026 | Medsuite

出版商 iData Research Inc. 商品編碼 925593
出版日期 內容資訊 英文 285 Pages
商品交期: 最快1-2個工作天內
價格
Medsuite:澳洲的整形外科生醫材料市場 (2020-2026年) Orthopedic Biomaterials Market Report Suite | Australia | 2020-2026 | Medsuite
出版日期: 2020年02月07日內容資訊: 英文 285 Pages
簡介

本報告提供澳洲的整形外科生醫材料的市場調查,市場背景,產品系列,骨移植片,去礦物質骨基質(DBM)移植片,合成骨等骨移植片替代品,整形外科用生長因子,玻尿酸粘性劑的市場規模的變化、預測,用了這些材料的整形外科治療數量,市場成長的各種影響因素分析,競爭環境,市場佔有率,主要企業簡介等資訊彙整。

產品的評估

  • 簡介
  • 產品系列
  • 法規上的課題、回收
  • 臨床試驗

澳洲的整形外科生醫材料市場:市場概要

  • 簡介
    • 移植骨替代物
    • 生長因子
    • 玻尿酸(HA)增稠劑
  • 匯率
  • 市場概要、趨勢分析
  • 成長推動因素、抑制因素
  • 企業佔有率分析
  • M&A
  • 企業簡介
    • Anika Therapeutics
    • Bioventus
    • DePuy Synthes
    • Ferring Pharmaceuticals
    • Fidia Pharmaceuticals
    • Genzyme (Sanofi Group)
    • Harvest Technologies (Terumo BCT)
    • Integra LifeSciences
    • Medtronic
    • Musculoskeletal Transplant Foundation (MTF)
    • NuVasive
    • Orthofix
    • RTI Surgical
    • Stryker
    • Vericel Corporation
    • Zimmer Biomet
  • SWOT分析

手術數量

  • 簡介
  • 手術數量:各類型
    • 骨移植
    • 使用了生長因子的手術
    • 玻尿酸補充

整形外科用移植骨替代物市場

  • 簡介
  • 市場概要
  • 市場分析、預測
    • 整體市場
    • 各材料
    • 各適應症
  • 成長推動因素、抑制因素
  • 企業佔有率分析

整形外科用生長因子市場

  • 簡介
    • BMP-2(Medtronic)
    • PDGF-BB(Wright Medical)
    • P-15合成小肽(Cerapedics)
    • P-15合成小肽(Biocomposites)
  • 成長推動因素、抑制因素
  • 企業佔有率分析

玻尿酸關節內補充市場

  • 簡介
  • 市場概要
  • 市場分析、預測
    • 整體市場
    • 單回注射
    • 3次注射
  • 成長推動因素、抑制因素
  • 企業佔有率分析

簡稱

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: iDATA_AUOB20_MS

The Australian orthopedic biomaterials market was valued at $63.8 million in 2019. This is expected to increase over the forecast period at a CAGR of 4.9% to reach $89.4 million.

With some exceptions, tissue supply for allografts and DBM allografts is constrained by the number of available donors. Furthermore, allografts are primarily sold by bone banks in Australia, which is attributed to a relatively high barrier to entry to the market for international companies. As the population ages, there will be a lower supply of eligible bone graft donors.

Surgical procedures that require the use of orthopedic biomaterials are generally associated with diseases and indications that become more prevalent in the population with an increase in age, such as osteoarthritis of the spine and knee. In 2019, over 15% of Australians were aged 65 and over; this proportion is projected to grow steadily over the forecast period, as further cohorts of baby boomers turn 65.

Single-injection HA viscosupplementation products are relatively new to the Australian market. Although three-injection products were available in Australia before single-injection products, the benefits of the latter are typically perceived to outweigh the favorable cost of the former. As a result, single-injection products are expected to continue to cannibalize three-injection products over the forecast period.

The full report suite on the Australian market for orthopedic biomaterials includes bone graft substitutes, which are represented by allografts, demineralized bone matrix (DBM) allografts and synthetics. This report also includes orthopedic growth factors and hyaluronic acid (HA) viscosupplementation.

TABLE OF CONTENTS

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF CHARTS

EXECUTIVE SUMMARY

AUSTRALIAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW

COMPETITIVE ANALYSIS

MARKET TRENDS

MARKET DEVELOPMENTS

PROCEDURE NUMBERS

MARKETS INCLUDED

KEY REPORT UPDATES

VERSION HISTORY

RESEARCH METHODOLOGY

  • Step 1: Project Initiation & Team Selection
  • Step 2: Prepare Data Systems and Perform Secondary Research
  • Step 3: Preparation for Interviews & Questionnaire Design
  • Step 4: Performing Primary Research
  • Step 5: Research Analysis: Establishing Baseline Estimates
  • Step 6: Market Forecast and Analysis
  • Step 7: Identify Strategic Opportunities
  • Step 8: Final Review and Market Release
  • Step 9: Customer Feedback and Market Monitoring

PRODUCT ASSESSMENT

  • 2.1 INTRODUCTION
  • 2.2 PRODUCT PORTFOLIOS
    • 2.2.1 Bone Graft Substitutes
    • 2.2.2 Growth Factors
      • 2.2.2.1 Other products
    • 2.2.3 Hyaluronic Acid Viscosupplementation (HAV)
  • 2.3 REGULATORY ISSUES AND RECALLS
    • 2.3.1 Bone Graft Substitutes
      • 2.3.1.1 Allografts
      • 2.3.1.1.1 MTF
      • 2.3.1.2 DBM
      • 2.3.1.2.1 AlloSource
      • 2.3.1.2.2 SeaSpine
      • 2.3.1.2.3 RTI Surgical
      • 2.3.1.3 Synthetics
      • 2.3.1.3.1 Abyrx
      • 2.3.1.3.2 Zimmer Biomet
    • 2.3.2 Growth Factors
      • 2.3.2.1.1 Medtronic
    • 2.3.3 Hyaluronic Acid Viscosupplementation
      • 2.3.3.1 Three-injection
      • 2.3.3.1.1 Ferring Pharmaceuticals
  • 2.4 CLINICAL TRIALS
    • 2.4.1 Bone Graft Substitutes
      • 2.4.1.1 Allografts
      • 2.4.1.1.1 Providence Medical Technology
      • 2.4.1.1.2 The University of Texas Health Science
      • 2.4.1.1.3 University of Winchester
      • 2.4.1.2 BDM
      • 2.4.1.2.1 K2M
      • 2.4.1.2.2 Zimmer Biomet
      • 2.4.1.3 Synthetics
      • 2.4.1.3.1 Baxter
      • 2.4.1.3.2 Bonesupport
      • 2.4.1.3.3 DePuy Synthes
      • 2.4.1.3.4 NuVasive
      • 2.4.1.3.5 RTI surgical
      • 2.4.1.3.6 Sunstar GUIDOR
      • 2.4.1.4 Other materials and comparison
      • 2.4.1.4.1 Seoul National University Hospital.
      • 2.4.1.4.2 Sewon Cellontech
      • 2.4.1.4.3 SurgaColl Technologies Limited
      • 2.4.1.4.4 University of Colorado
      • 2.4.1.4.5 University of Padova
    • 2.4.2 Growth Factors
      • 2.4.2.1.1 Bioventus
      • 2.4.2.1.2 Cerapedics
      • 2.4.2.1.3 CGBio
      • 2.4.2.1.4 Isto
      • 2.4.2.1.5 Medtronic
      • 2.4.2.1.6 NuVasive
      • 2.4.2.1.7 Wright
      • 2.4.2.1.8 Others
    • 2.4.3 Hyaluronic Acid Viscosupplementation
      • 2.4.3.1.1 Anika Therapeutics
      • 2.4.3.1.2 Bioventus
      • 2.4.3.1.3 Cario University
      • 2.4.3.1.4 Ferring Pharmaceuticals
      • 2.4.3.1.5 Federal University of Minas Gerais
      • 2.4.3.1.6 Fidia Pharma USA Inc.
      • 2.4.3.1.7 Istituto Ortopedico Rizzoli
      • 2.4.3.1.8 University Hospital
      • 2.4.3.1.9 Universidade Nova de Lisboa

AUSTRALIAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW

  • 3.1 INTRODUCTION
    • 3.1.1 Bone Graft Substitutes
    • 3.1.2 Growth Factors
    • 3.1.3 Hyaluronic Acid (HA) Viscosupplementation
  • 3.2 CURRENCY EXCHANGE RATE
  • 3.3 MARKET OVERVIEW AND TREND ANALYSIS
  • 3.4 DRIVERS AND LIMITERS
    • 3.4.1 Market Drivers
    • 3.4.2 Market Limiters
  • 3.5 COMPETITIVE MARKET SHARE ANALYSIS
  • 3.6 MERGERS AND ACQUISITIONS
  • 3.7 COMPANY PROFILES
    • 3.7.1 Anika Therapeutics
    • 3.7.2 Bioventus
    • 3.7.3 DePuy Synthes
    • 3.7.4 Ferring Pharmaceuticals
    • 3.7.5 Fidia Pharmaceuticals
    • 3.7.6 Genzyme (Sanofi Group)
    • 3.7.7 Harvest Technologies (Terumo BCT)
    • 3.7.8 Integra LifeSciences
    • 3.7.9 Medtronic
    • 3.7.10 Musculoskeletal Transplant Foundation (MTF)
    • 3.7.11 NuVasive
    • 3.7.12 Orthofix
    • 3.7.13 RTI Surgical
    • 3.7.14 Stryker
    • 3.7.15 Vericel Corporation (formerly Aastrom Bioscience)
    • 3.7.16 Zimmer Biomet
  • 3.8 SWOT ANALYSIS
    • 3.8.1 Anika Therapeutics
    • 3.8.2 Bioventus
    • 3.8.3 DePuy Synthes
    • 3.8.4 Ferring Pharmaceuticals
    • 3.8.5 Fidia Pharmaceuticals
    • 3.8.7 Harvest Technologies (Terumo BCT)
    • 3.8.8 Integra LifeSciences
    • 3.8.9 Medtronic
    • 3.8.10 Musculoskeletal Transplant Foundation (MTF)
    • 3.8.11 NuVasive
    • 3.8.12 Orthofix
    • 3.8.14 Stryker
    • 3.8.15 Vericel Corporation (formerly Aastrom Bioscience)
    • 3.8.16 Zimmer Biomet

PROCEDURE NUMBERS

  • 4.1 INTRODUCTION
  • 4.2 PROCEDURES
    • 4.2.1 Orthopedic Biomaterial Procedures by Segment
    • 4.2.2 Orthopedic Bone Grafting Procedures
      • 4.2.2.1 Units per Procedure by Indication
      • 4.2.2.2 Orthopedic Bone Grafting Procedures by Material
      • 4.2.2.2.1 Autograft Procedures by Indication
      • 4.2.2.2.2 Allograft Procedures by Indication
      • 4.2.2.2.3 DBM Allograft Procedures by Indication
      • 4.2.2.2.4 Synthetic Procedures by Indication
      • 4.2.2.3 Orthopedic Bone Grafting Procedures by Indication
    • 4.2.3 Orthopedic Growth Factor Procedures
    • 4.2.4 Hyaluronic Acid Supplementation Procedures
      • 4.2.4.1 Hyaluronic Acid Supplementation Procedures by Injection Cycle

ORTHOPEDIC BONE GRAFT SUBSTITUTE MARKET

  • 5.1 INTRODUCTION
  • 5.2 MARKET OVERVIEW
    • 5.2.1 Orthopedic Bone Graft Substitute Market by Material
    • 5.2.2 Orthopedic Bone Graft Substitute Market by Indication
  • 5.3 MARKET ANALYSIS AND FORECAST
    • 5.3.1 Total Orthopedic Bone Graft Substitute Market
    • 5.3.2 Orthopedic Bone Graft Substitute Market by Material
      • 5.3.2.1 Allograft Bone Graft Substitute Market
      • 5.3.2.1.1 Allograft Bone Graft Substitute Market by Indication
      • 5.3.2.2 Demineralized Bone Matrix Allograft Bone Graft Substitute Market
      • 5.3.2.2.1 Demineralized Bone Matrix Allograft Bone Graft Substitute Market by Indication
      • 5.3.2.3 Synthetic Bone Graft Substitute Market
      • 5.3.2.3.1 Synthetic Bone Graft Substitute Market by Indication
    • 5.3.3 Orthopedic Bone Graft Substitute Market by Indication
      • 5.3.3.1 Spine Bone Graft Substitute Market
      • 5.3.3.2 Cervical Spine Bone Graft Substitute Market
      • 5.3.3.3 Thoracolumbar Spine Bone Graft Substitute Market
      • 5.3.3.4 Trauma Bone Graft Substitute Market
      • 5.3.3.5 Non-Union Trauma Bone Graft Substitute Market
      • 5.3.3.6 Fresh Fracture Trauma Bone Graft Substitute Market
      • 5.3.3.7 Large Joint Reconstruction Bone Graft Substitute Market
      • 5.3.3.8 Hip Reconstruction Bone Graft Substitute Market
      • 5.3.3.9 Knee Reconstruction Bone Graft Substitute Market
      • 5.3.3.10 Foot Reconstruction Bone Graft Substitute Market
      • 5.3.3.11 Craniomaxillofacial Bone Graft Substitute Market
      • 5.3.3.12 Oncology Bone Graft Substitute Market
  • 5.4 DRIVERS AND LIMITERS
    • 5.4.1 Market Drivers
    • 5.4.2 Market Limiters
  • 5.5 COMPETITIVE MARKET SHARE ANALYSIS

ORTHOPEDIC GROWTH FACTOR MARKET

  • 6.1 INTRODUCTION
    • 6.1.1 BMP-2 (Medtronic)
    • 6.1.2 PDGF-BB (Wright Medical)
    • 6.1.3 P-15 Synthetic Small Peptide (Cerapedics)
    • 6.1.4 P-15 Synthetic Small Peptide (Biocomposites)
  • 6.2 MARKET ANALYSIS AND FORECAST
  • 6.3 DRIVERS AND LIMITERS
    • 6.3.1 Market Drivers
    • 6.3.2 Market Limiters
  • 6.4 COMPETITIVE MARKET SHARE ANALYSIS

HYALURONIC ACID VISCOSUPPLEMENTATION MARKET

  • 7.1 INTRODUCTION
    • 7.1.1 Benefits of Viscosupplementation
    • 7.1.2 Synovial Fluid
  • 7.2 MARKET OVERVIEW
  • 7.3 MARKET ANALYSIS AND FORECAST
    • 7.3.1 Total Hyaluronic Acid Viscosupplementation Market
    • 7.3.2 Single-Injection Hyaluronic Acid Viscosupplementation Market
    • 7.3.3 Three-Injection Hyaluronic Acid Viscosupplementation Market
  • 7.4 DRIVERS AND LIMITERS
    • 7.4.1 Market Drivers
    • 7.4.2 Market Limiters
  • 7.5 COMPETITIVE MARKET SHARE ANALYSIS

ABBREVIATIONS

LIST OF CHARTS

  • Chart 1 1: Orthopedic Biomaterials Market by Segment, Australia, 2016 - 2026
  • Chart 1 2: Orthopedic Biomaterials Market Overview, Australia, 2019 & 2026
  • Chart 3 1: Orthopedic Biomaterials Market by Segment, Australia, 2016 - 2026
  • Chart 3 2: Orthopedic Biomaterials Market Breakdown, Australia, 2019
  • Chart 3 3: Orthopedic Biomaterials Market Breakdown, Australia, 2026
  • Chart 3 4: Growth Rates by Segment, Orthopedic Biomaterials Market, Australia, 2016 - 2026
  • Chart 3 5: Leading Competitors, Orthopedic Biomaterials Market, Australia, 2019
  • Chart 4 1: Orthopedic Biomaterials Market by Segment, Australia, 2016 - 2026
  • Chart 4 2: Orthopedic Bone Grafting Procedures by Material, Australia, 2016 - 2026
  • Chart 4 3: Autograft Procedures by Indication, Australia, 2016 - 2026
  • Chart 4 4: Allograft Procedures by Indication, Australia, 2016 - 2026
  • Chart 4 5: DBM Allograft Procedures by Indication, Australia, 2016 - 2026
  • Chart 4 6: Synthetic Procedures by Indication, Australia, 2016 - 2026
  • Chart 4 7: Orthopedic Bone Grafting Procedures by Indication, Australia, 2016 - 2026
  • Chart 4 8: Orthopedic Growth Factor Procedures, Australia, 2016 - 2026
  • Chart 4 9: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Australia, 2016 - 2026
  • Chart 5 1: Orthopedic Bone Graft Substitute Market by Material, Australia, 2016 - 2026
  • Chart 5 2: Orthopedic Bone Graft Substitute Market Breakdown by Material, Australia, 2019
  • Chart 5 3: Orthopedic Bone Graft Substitute Market Breakdown by Material, Australia, 2026
  • Chart 5 4: Orthopedic Bone Graft Substitute Market by Indication, Australia, 2016 - 2026
  • Chart 5 5: Orthopedic Bone Graft Substitute Market Breakdown by Indication, Australia, 2019
  • Chart 5 6: Orthopedic Bone Graft Substitute Market Breakdown by Indication, Australia, 2026
  • Chart 5 7: Total Orthopedic Bone Graft Substitute Market, Australia, 2016 - 2026
  • Chart 5 8: Allograft Bone Graft Substitute Market, Australia, 2016 - 2026
  • Chart 5 9: Allograft Bone Graft Substitute Market by Indication, Australia, 2016 - 2026
  • Chart 5 10: Demineralized Bone Matrix Allograft Bone Graft Substitute Market, Australia, 2016 - 2026
  • Chart 5 11: Demineralized Bone Matrix Allograft Bone Graft Substitute Market by Indication, Australia, 2016 - 2026
  • Chart 5 12: Synthetic Bone Graft Substitute Market, Australia, 2016 - 2026
  • Chart 5 13: Synthetic Bone Graft Substitute Market by Indication, Australia, 2016 - 2026
  • Chart 5 14: Spine Bone Graft Substitute Market, Australia, 2016 - 2026
  • Chart 5 15: Cervical Spine Bone Graft Substitute Market, Australia, 2016 - 2026
  • Chart 5 16: Thoracolumbar Spine Bone Graft Substitute Market, Australia, 2016 - 2026
  • Chart 5 17: Trauma Bone Graft Substitute Market, Australia, 2016 - 2026
  • Chart 5 18: Non-Union Trauma Bone Graft Substitute Market, Australia, 2016 - 2026
  • Chart 5 19: Fresh Fracture Trauma Bone Graft Substitute Market, Australia, 2016 - 2026
  • Chart 5 20: Large Joint Reconstruction Bone Graft Substitute Market, Australia, 2016 - 2026
  • Chart 5 21: Hip Reconstruction Bone Graft Substitute Market, Australia, 2016 - 2026
  • Chart 5 22: Knee Reconstruction Bone Graft Substitute Market, Australia, 2016 - 2026
  • Chart 5 23: Foot Reconstruction Bone Graft Substitute Market, Australia, 2016 - 2026
  • Chart 5 24: Craniomaxillofacial Bone Graft Substitute Market, Australia, 2016 - 2026
  • Chart 5 25: Oncology Bone Graft Substitute Market, Australia, 2016 - 2026
  • Chart 5 26: Leading Competitors, Orthopedic Bone Graft Substitute Market, Australia, 2019
  • Chart 6 1: Orthopedic Growth Factor Market, Australia, 2016 - 2026
  • Chart 6 2: Leading Competitors, Orthopedic Growth Factor Market, Australia, 2019
  • Chart 7 1: Hyaluronic Acid Viscosupplementation Market by Segment, Australia, 2016 - 2026
  • Chart 7 2: Hyaluronic Acid Viscosupplementation Market Breakdown, Australia, 2019
  • Chart 7 3: Hyaluronic Acid Viscosupplementation Market Breakdown, Australia, 2026
  • Chart 7 4: Total Hyaluronic Acid Viscosupplementation Market, Australia, 2016 - 2026
  • Chart 7 5: Single-Injection Hyaluronic Acid Viscosupplementation Market, Australia, 2016 - 2026
  • Chart 7 6: Three-Injection Hyaluronic Acid Viscosupplementation Market, Australia, 2016 - 2026
  • Chart 7 7: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, Australia, 2019

LIST OF FIGURES

  • Figure 1 1: Orthopedic Biomaterials Market Share Ranking by Segment, Australia, 2019
  • Figure 1 2: Companies Researched in this Report
  • Figure 1 3: Factors Impacting the Orthopedic Biomaterials Market by Segment, Australia
  • Figure 1 4: Recent Events in the Orthopedic Biomaterials Market, Australia, 2016 - 2019
  • Figure 1 5: Orthopedic Biomaterials Procedures Covered, Australia
  • Figure 1 6: Orthopedic Biomaterials Markets Covered (1 of 2)
  • Figure 1 7: Orthopedic Biomaterials Markets Covered (2 of 2)
  • Figure 1 8: Key Report Updates
  • Figure 1 9: Version History
  • Figure 2 1: Bone Graft Substitutes Products by Company (1 of 4)
  • Figure 2 2: Bone Graft Substitutes Products by Company (2 of 4)
  • Figure 2 3: Bone Graft Substitutes Products by Company (3 of 4)
  • Figure 2 4: Bone Graft Substitutes Products by Company (4 of 4)
  • Figure 2 5: Growth Factor Products by Company
  • Figure 2 6: Hyaluronic Acid Viscosupplementation by Products by Company
  • Figure 2 7: Class 2 Device Recall Musculoskeletal Transplant Foundation Allofix Insertion Kit
  • Figure 2 8: Class 2 Device Recall AlloFuse DBM Putty 5cc
  • Figure 2 9: Class 2 Device Recall Accell Evo3c Demineralized Bone Matrix Putty
  • Figure 2 10: Class 2 Device Recall RTI Biologics BioSet IC RT Paste 2 cc
  • Figure 2 11: Class 2 Device Recall Hemostatic Bone Putty
  • Figure 2 12: Class 2 Device Recall Endobon Xenograft Granules
  • Figure 2 13: Class 2 Device Recall Endobon Xenograft Granules
  • Figure 2 14: Class 2 Device Recall INFUSE Bone Graft X SMALL KIT
  • Figure 2 15: Class 3 Device Recall Euflexxa (1 sodium hyaluronate)
  • Figure 2 16: Evaluation of DTRAX Graft in Patients with Cervical Degenerative Disc Disease
  • Figure 2 17: Ridge Preservation Using FDBA and a Collagen Wound Dressing in Molar Sites.
  • Figure 2 18: Assessing Physical Activity Levels of Patients Following HTO.
  • Figure 2 19: Evaluation of Fusion Rate Using K2M VESUVIUS® Demineralized Fibers with K2M EVEREST® Spinal System
  • Figure 2 20: Evaluation of Zimmer Puros® Allograft vs. Creos™ Allograft for Alveolar Ridge Preservation
  • Figure 2 21: Synthetic Bone Graft Substitute vs. Autologous Spongiosa in Revision Anterior Cruciate Ligament Reconstruction
  • Figure 2 22: Cerament Treatment of Fracture Defects (CERTiFy)
  • Figure 2 23: Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute (BAGvsTCP)
  • Figure 2 24: Evaluation of Fusion Rate of Anterior Cervical Discectomy and Fusion (ACDF) Using Cervios ChronOs™ and Bonion™
  • Figure 2 25: AttraX® Putty vs. Autograft in XLIF®
  • Figure 2 26: Comparison of nanOss Bioactive with Autograft and Bone Marrow Aspirate to Autograft in the Posterolateral Spine
  • Figure 2 27: Assessment of nanOss Bioactive 3D in the Posterolateral Spine
  • Figure 2 28: Assessment of Ridge Preservation Using Moldable Beta-tricalcium Phosphate Bone Grafting System
  • Figure 2 29: Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy
  • Figure 2 30: Efficacy and Safety of SurgiFill™ on Spinal Fusion
  • Figure 2 31: Assessment of HydroxyColl Bone Graft Substitute in High Tibial Osteotomy Wedge Grafting. (HColl_HTO)
  • Figure 2 32: Outcomes of the Evans Calcaneal Lengthening Based on Bone Grafting Material
  • Figure 2 33: Deproteinized Bovine Bone in Alveolar Bone Critical Size Defect (>2cm) Secondary to Cyst Removal
  • Figure 2 34: A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP®
  • Figure 2 35: The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumented Posterolateral Spondylodesis Operation
  • Figure 2 36: Clinical Study of Injectable Ceramics Bone Graft Substitute Containing rhBMP-2
  • Figure 2 37: Prospective Study of Safety and Efficacy of InQu® Bone Graft Extender in Lumbar Interbody Fusion Surgery (Intebody)
  • Figure 2 38: A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1
  • Figure 2 39: Clinical Study of INFUSE® Bone Graft Compared to Autogenous Bone Graft for Vertical Ridge Augmentation
  • Figure 2 40: Parallel Study Between BMP-2 and Autologous Bone Graft After Ilizarow Treatment
  • Figure 2 41: RCT of AttraX® Putty vs. Autograft in Instrumented Posterolateral Spinal Fusion (AxA)
  • Figure 2 42: Long-term Safety and Effectiveness of AUGMENT® Bone Graft Compared to Autologous Bone Graft
  • Figure 2 43: rhBMP-2 vs Autologous Bone Grafting for the Treatment of Non-union of the Docking Site in Tibial Bone Transport
  • Figure 2 44: Evaluation of Radiculitis Following Use of Bone Morphogenetic Protein-2 for Interbody Arthrodesis in Spinal Surgery
  • Figure 2 45: Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow-Up (Cingal17-02)
  • Figure 2 46: HyaloFAST Trial for Repair of Articular Cartilage in the Knee (FastTRACK)
  • Figure 2 47: Effectiveness of Two Hyaluronic Acids in Osteoarthritis of the Knee
  • Figure 2 48: The Effect of Topical Application of Hyaluronic Acid on Immediate Dental Implant
  • Figure 2 49: To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knees After Hyaluronic Acid Injection
  • Figure 2 50: Use of Hyaluronic Acid as a Therapeutic Strategy for Bone Repair in Humans
  • Figure 2 51: Two Weekly Intra-articular Hyaluronan Knee Injections, Given One Week Apart, of HYMOVIS Combined With a Physical Exercise Program (PEP) Compared to PEP Alone, in a Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA)
  • Figure 2 52: Comparative Assessment of Viscosupplementation With Polynucleotides and Hyaluronic Acid (PNHA1401)
  • Figure 2 53: Trial Comparing Botulin Toxin Versus Hyaluronic Acid by Intra-articular Injection (GOTOX)
  • Figure 2 54: Trial to Assess the Structural Effect and Long-term Symptomatic Relief of Intra-articular Injections of HA (ViscOA)
  • Figure 3 1: Currency Exchange Rate, 2019
  • Figure 3 2: Orthopedic Biomaterials Market by Segment, Australia, 2016 - 2026 (US$M)
  • Figure 3 3: Orthopedic Biomaterials Market by Segment, Australia, 2016 - 2026 (AU$M)
  • Figure 3 4: Orthopedic Biomaterials Market Growth by Segment, Australia, 2016 - 2026
  • Figure 3 5: Drivers and Limiters, Orthopedic Biomaterials Market, Australia, 2019
  • Figure 3 6: Leading Competitors, Orthopedic Biomaterials Market, Australia, 2019
  • Figure 3 7: SWOT Analysis, Anika Therapeutics (1 of 2)
  • Figure 3 8: SWOT Analysis, Anika Therapeutics (2 of 2)
  • Figure 3 9: SWOT Analysis, Bioventus (1 of 2)
  • Figure 3 10: SWOT Analysis, Bioventus (2 of 2)
  • Figure 3 11: SWOT Analysis, DePuy Synthes
  • Figure 3 12: SWOT Analysis, Ferring Pharmaceuticals
  • Figure 3 13: SWOT Analysis, Fidia Pharmaceuticals
  • Figure 3 14: SWOT Analysis, Genzyme (Sanofi)
  • Figure 3 15: SWOT Analysis, Harvest Technologies
  • Figure 3 16: SWOT Analysis, Integra LifeSciences
  • Figure 3 17: SWOT Analysis, Medtronic
  • Figure 3 18: SWOT Analysis, MTF
  • Figure 3 19: SWOT Analysis, NuVasive
  • Figure 3 20: SWOT Analysis, Orthofix
  • Figure 3 21: SWOT Analysis, RTI Surgical
  • Figure 3 22: SWOT Analysis, Stryker
  • Figure 3 23: SWOT Analysis, Vericel Corporation
  • Figure 3 24: SWOT Analysis, Zimmer Biomet (1 of 2)
  • Figure 3 25: SWOT Analysis, Zimmer Biomet (2 of 2)
  • Figure 4 1: Orthopedic Biomaterials Procedures by Segment, Australia, 2016 - 2026
  • Figure 4 2: Units per Procedure by Indication, Bone Graft Substitute Market, Australia, 2016- 2026
  • Figure 4 3: Orthopedic Bone Grafting Procedures by Material, Australia, 2016 - 2026
  • Figure 4 4: Autograft Procedures by Indication, Australia, 2016 - 2026 (1 of 2)
  • Figure 4 5: Autograft Procedures by Indication, Australia, 2016 - 2026 (2 of 2)
  • Figure 4 6: Allograft Procedures by Indication, Australia, 2016 - 2026 (1 of 2)
  • Figure 4 7: Allograft Procedures by Indication, Australia, 2016 - 2026 (2 of 2)
  • Figure 4 8: DBM Allograft Procedures by Indication, Australia, 2016 - 2026 (1 of 2)
  • Figure 4 9: DBM Allograft Procedures by Indication, Australia, 2016 - 2026 (2 of 2)
  • Figure 4 10: Synthetic Procedures by Indication, Australia, 2016 - 2026 (1 of 2)
  • Figure 4 11: Synthetic Procedures by Indication, Australia, 2016 - 2026 (2 of 2)
  • Figure 4 12: Orthopedic Bone Grafting Procedures by Indication, Australia, 2016 - 2026 (1 of 2)
  • Figure 4 13: Orthopedic Bone Grafting Procedures by Indication, Australia, 2016 - 2026 (2 of 2)
  • Figure 4 14: Orthopedic Growth Factor Procedures, Australia, 2016 - 2026
  • Figure 4 15: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Australia, 2016 - 2026
  • Figure 5 1: Orthopedic Bone Graft Substitute Market by Material, Australia, 2016 - 2026 (US$M)
  • Figure 5 2: Orthopedic Bone Graft Substitute Market by Material, Australia, 2016 - 2026 (AU$M)
  • Figure 5 3: Orthopedic Bone Graft Substitute Market by Indication, Australia, 2016 - 2026 (US$M)
  • Figure 5 4: Orthopedic Bone Graft Substitute Market by Indication, Australia, 2016 - 2026 (AU$M)
  • Figure 5 5: Total Orthopedic Bone Graft Substitute Market, Australia, 2016 - 2026
  • Figure 5 6: Allograft Bone Graft Substitute Market, Australia, 2016 - 2026
  • Figure 5 7: Allograft Bone Graft Substitute Market by Indication, Australia, 2016 - 2026 (US$M)
  • Figure 5 8: Spine Allograft Market, Australia, 2016 - 2026
  • Figure 5 9: Cervical Spine Allograft Market, Australia, 2016 - 2026
  • Figure 5 10: Thoracolumbar Spine Allograft Market, Australia, 2016 - 2026
  • Figure 5 11: Trauma Allograft Market, Australia, 2016 - 2026
  • Figure 5 12: Non-Union Trauma Allograft Market, Australia, 2016 - 2026
  • Figure 5 13: Fresh Fracture Trauma Allograft Market, Australia, 2016 - 2026
  • Figure 5 14: Large Joint Reconstruction Allograft Market, Australia, 2016 - 2026
  • Figure 5 15: Hip Reconstruction Allograft Market, Australia, 2016 - 2026
  • Figure 5 16: Knee Reconstruction Allograft Market, Australia, 2016 - 2026
  • Figure 5 17: Foot Reconstruction Allograft Market, Australia, 2016 - 2026
  • Figure 5 18: Craniomaxillofacial Allograft Market, Australia, 2016 - 2026
  • Figure 5 19: Oncology Allograft Market, Australia, 2016 - 2026
  • Figure 5 20: Demineralized Bone Matrix Allograft Bone Graft Substitute Market, Australia, 2016 - 2026
  • Figure 5 21: Demineralized Bone Matrix Allograft Bone Graft Substitute Market by Indication, Australia, 2016 - 2026 (US$M)
  • Figure 5 22: Spine DBM Allograft Market, Australia, 2016 - 2026
  • Figure 5 23: Cervical Spine DBM Allograft Market, Australia, 2016 - 2026
  • Figure 5 24: Thoracolumbar Spine DBM Allograft Market, Australia, 2016 - 2026
  • Figure 5 25: Trauma DBM Allograft Market, Australia, 2016 - 2026
  • Figure 5 26: Non-Union Trauma DBM Allograft Market, Australia, 2016 - 2026
  • Figure 5 27: Fresh Fracture Trauma DBM Allograft Market, Australia, 2016 - 2026
  • Figure 5 28: Large Joint Reconstruction DBM Allograft Market, Australia, 2016 - 2026
  • Figure 5 29: Hip Reconstruction DBM Allograft Market, Australia, 2016 - 2026
  • Figure 5 30: Knee Reconstruction DBM Allograft Market, Australia, 2016 - 2026
  • Figure 5 31: Foot Reconstruction DBM Allograft Market, Australia, 2016 - 2026
  • Figure 5 32: Craniomaxillofacial DBM Allograft Market, Australia, 2016 - 2026
  • Figure 5 33: Oncology DBM Allograft Market, Australia, 2016 - 2026
  • Figure 5 34: Synthetic Bone Graft Substitute Market, Australia, 2016 - 2026
  • Figure 5 35: Synthetic Bone Graft Substitute Market by Indication, Australia, 2016 - 2026 (US$M)
  • Figure 5 36: Spine Synthetic Market, Australia, 2016 - 2026
  • Figure 5 37: Cervical Spine Synthetic Market, Australia, 2016 - 2026
  • Figure 5 38: Thoracolumbar Spine Synthetic Market, Australia, 2016 - 2026
  • Figure 5 39: Trauma Synthetic Market, Australia, 2016 - 2026
  • Figure 5 40: Non-Union Trauma Synthetic Market, Australia, 2016 - 2026
  • Figure 5 41: Fresh Fracture Trauma Synthetic Market, Australia, 2016 - 2026
  • Figure 5 42: Large Joint Reconstruction Synthetic Market, Australia, 2016 - 2026
  • Figure 5 43: Hip Reconstruction Synthetic Market, Australia, 2016 - 2026
  • Figure 5 44: Knee Reconstruction Synthetic Market, Australia, 2016 - 2026
  • Figure 5 45: Foot Reconstruction Synthetic Market, Australia, 2016 - 2026
  • Figure 5 46: Craniomaxillofacial Synthetic Market, Australia, 2016 - 2026
  • Figure 5 47: Oncology Synthetic Market, Australia, 2016 - 2026
  • Figure 5 48: Spine Bone Graft Substitute Market, Australia, 2016 - 2026
  • Figure 5 49: Cervical Spine Bone Graft Substitute Market, Australia, 2016 - 2026
  • Figure 5 50: Thoracolumbar Spine Bone Graft Substitute Market, Australia, 2016 - 2026
  • Figure 5 51: Trauma Bone Graft Substitute Market, Australia, 2016 - 2026
  • Figure 5 52: Non-Union Trauma Bone Graft Substitute Market, Australia, 2016 - 2026
  • Figure 5 53: Fresh Fracture Trauma Bone Graft Substitute Market, Australia, 2016 - 2026
  • Figure 5 54: Large Joint Reconstruction Bone Graft Substitute Market, Australia, 2016 - 2026
  • Figure 5 55: Hip Reconstruction Bone Graft Substitute Market, Australia, 2016 - 2026
  • Figure 5 56: Knee Reconstruction Bone Graft Substitute Market, Australia, 2016 - 2026
  • Figure 5 57: Foot Reconstruction Bone Graft Substitute Market, Australia, 2016 - 2026
  • Figure 5 58: Craniomaxillofacial Bone Graft Substitute Market, Australia, 2016 - 2026
  • Figure 5 59: Oncology Bone Graft Substitute Market, Australia, 2016 - 2026
  • Figure 5 60: Drivers and Limiters, Orthopedic Bone Graft Substitute Market, Australia, 2019
  • Figure 5 61: Leading Competitors, Orthopedic Bone Graft Substitute Market, Australia, 2019
  • Figure 6 1: Orthopedic Growth Factor Market, Australia, 2016 - 2026
  • Figure 6 2: Drivers and Limiters, Orthopedic Growth Factor Market, Australia, 2019
  • Figure 6 3: Leading Competitors, Orthopedic Growth Factor Market, Australia, 2019
  • Figure 7 1: Hyaluronic Acid Viscosupplementation Market by Segment, Australia, 2016 - 2026 (US$M)
  • Figure 7 2: Hyaluronic Acid Viscosupplementation Market by Segment, Australia, 2016 - 2026 (AU$M)
  • Figure 7 3: Total Hyaluronic Acid Viscosupplementation Market, Australia, 2016 - 2026
  • Figure 7 4: Single-Injection Hyaluronic Acid Viscosupplementation Market, Australia, 2016 - 2026
  • Figure 7 5: Three-Injection Hyaluronic Acid Viscosupplementation Market, Australia, 2016 - 2026
  • Figure 7 6: Drivers and Limiters, Hyaluronic Acid Viscosupplementation Market, Australia, 2019
  • Figure 7 7: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, Australia, 2019